Moderna at forefront of mRNA vaccines in infectious diseases

29 January 2024

The global messenger ribonucleic acid (mRNA) vaccine market currently consists entirely of vaccines for COVID-19. The rapid sequencing of the SARS-CoV-2 viral genome and the subsequent development of these jabs in response to the pandemic led to the authorization of the first of these vaccines in December 2020.

By now, several pharma companies have mRNA vaccines in late-stage development for other infectious diseases, with US biotech major Moderna (Nasdaq: MRNA) dominating in terms of research and development (R&D) investment in mRNA vaccines, according to GlobalData.

"Approval of mRNA vaccines is expected for other infectious diseases, especially influenza"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK